Management of the predementia stage of Alzheimer’s disease, complicated with hypoactive delirium
https://doi.org/10.30629/2658-7947-2020-25-6-40-46
Abstract
Alzheimer’s disease (AD) is the most common neurodegenerative disorder in elderly population leading to the development of dementia. The emergence of modern diagnostic approaches makes possible reveal AD at predementia stage and study new drugs with pathogenetic and neuroprotective properties before severe cognitive impairment (dementia) arises. We present a description of patient with amnestic type of mild cognitive impairment with subsequent follow-up for more than two years. AD presence in mentioned patient was confirmed by evaluation of specific clinical, laboratory and instrumental biomarkers. Therapy with akatinol memantine (one of the main antidementia drugs in AD) at dose 20 mg/day was accompanied by cognitive defect stabilization. After two years of therapy acute severe decompensation related to hypoactive delirium due to respiratory infection was observed, which was followed by marked cognitive status deterioration. Daily dose of akatinol memantine was increased to 30 mg with subsequent restoration of baseline cognitive status. Possible mechanisms of akatinol memantine action and its effects in management of geriatric patients with AD including role in delirium therapy are discussed.
About the Authors
O. N. Tkacheva
Pirogov Russian National Research Medical University (RNRMU), Russian Clinical and Research Center of Gerontology
Russian Federation
Moscow
Russian Federation
Moscow
M. A. Cherdak
Pirogov Russian National Research Medical University (RNRMU), Russian Clinical and Research Center of Gerontology
Russian Federation
Moscow
Russian Federation
Moscow
E. A. Mkhitaryan
Pirogov Russian National Research Medical University (RNRMU), Russian Clinical and Research Center of Gerontology
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Tiwari S., Atluri V., Kaushik A., Yndart A., Nair M. Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics. Int. J. Nanomedicine. 2019;14:5541–5554. htpps://doi.org/10.2147/IJN.S200490
2. Jack C.R. Jr, Albert M.S., Knopman D.S., McKhann G.M., Sperling R.A., Carrillo M.C. et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):257–62. htpps://doi.org/10.1016/j.jalz.2011.03.004
3. Matsunaga S., Fujishiro H., Takechi H. Efficacy and Safety of Cholinesterase Inhibitors for Mild Cognitive Impairment: A Systematic Review and Meta-Analysis. J. Alzheimers Dis. 2019;71(2):513–523. htpps://doi.org/10.3233/JAD-190546
4. Danysz W., Parsons C.G. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer’s disease: preclinical evidence. Int. J. Geriatr. Psychiatry. 2003;18(Suppl 1):S23–32. htpps://doi.org/10.1002/gps.938
5. Folch J., Busquets O., Ettcheto M., Sánchez-López E., CastroTorres R.D., Verdaguer E. et al. Memantine for the Treatment of Dementia: A Review on its Current and Future Applications. J. Alzheimers Dis. 2018;62(3):1223–1240. htpps://doi.org/10.3233/JAD-170672
6. Chen Z.Z., Yang D.D., Zhao Z., Yan H., Ji J., Sun X.L. Memantine mediates neuroprotection via regulating neurovascular unit in a mouse model of focal cerebral ischemia. Life Sci. 2016;150:8–14. htpps://doi.org/10.1016/j.lfs.2016.02.081
7. Mkhitaryan E.А., Cherdak M.A. New options for differential diagnosis and treatment of Alzheimer’s disease at the stage of mild cognitive impairment. Effektivnaya farmakoterapiya. 2020;16(23):22–28. (in Russ.) htpps://doi.org/10.33978/2307-3586-2020-16-23-22-28
8. Uspenskaya O.V., Yakhno N.N. The effect of memantine on the cognitive functions of patients with amnestic mild cognitive impairment (clinical, psychological and neurochemical study). Nevrol. zhurn. 2009;14(3): 49–54. (in Russ.)
9. Yakhno N.N., Preobrazhenskaya I.S., Zaharov V.V., Mkhitaryan E.A. The efficacy of akatinol memantine in patients with non-dementia cognitive impairment. Results of multicenter clinical study. Nevrol. zhurn. 2010;15(2):52–58. (in Russ.)
10. Levin O.S., Vasenina E.E., Gankinа O.A. Diagnosis and treatment of mild cognitive impairment. Sovremennaya terapiya v psikhiatrii i nevrologii. 2014;4:4–9. (in Russ.) URL: https://cyberleninka.ru/article/n/diagnostika-i-lechenie-umerennogokognitivnogo-rasstroystva
11. Scheltens P., Launer L.J., Barkhof F., Weinstein H.C., van Gool W.A. Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. J. Neurol. 1995;242(9):557–560. htpps://doi.org/10.1007/BF00868807
12. Wahlund L.O., Barkhof F., Fazekas F., Bronge L., Augustin M., Sjögren M. et al. European Task Force on Age-Related White Matter Changes. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001;32(6):1318–1322. htpps://doi.org/10.1161/01.str.32.6.1318
13. Tapiola T., Alafuzoff I., Herukka S.K., Parkkinen L., Hartikainen P., Soininen H. et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch. Neurol. 2009;66(3):382–389. htpps://doi.org/10.1001/archneurol.2008.596
14. Li G., Sokal I., Quinn J.F., Leverenz J.B., Brodey M., Schellenberg G.D. et al. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology. 2007;69(7):631–639. htpps://doi.org/10.1212/01.wnl.0000267428.62582.aa
15. Ding D., Zhao Q., Guo Q., Liang X., Luo J., Yu L. et al. Shanghai Aging Study (SAS). Progression and predictors of mild cognitive impairment in Chinese elderly: A prospective follow-up in the Shanghai Aging Study. Alzheimers Dement (Amst). 2016;4:28–36. htpps://doi.org/10.1016/j.dadm.2016.03.004
16. Tocco M., Bayles K., Lopez O.L., Hofbauer R.K., Pejović V., Miller M.L. et al. Effects of memantine treatment on language abilities and functional communication: A review of data. Aphasiology. 2014;28:236–257. htpps://doi.org/10.1080/02687038.2013.838617
17. Ambrozi L., Danielczyk W. Treatment of impaired cerebral function in psychogeriatric patients with memantine — results of a phase II double-blind study. Pharmacopsychiatry. 1988;21(3):144–146. htpps://doi.org/10.1055/s-2007-1014666
18. de Lange E., Verhaak P.F., van der Meer K. Prevalence, presentation and prognosis of delirium in older people in the population, at home and in long term care: a review. Int. J. Geriatr. Psychiatry. 2013;28(2):127–134. htpps://doi.org/10.1002/gps.3814
19. Ahmed S., Leurent B., Sampson E.L. Risk factors for incident delirium among older people in acute hospital medical units: a systematic review and meta-analysis. Age Ageing. 2014;43(3):326–333. htpps://doi.org/10.1093/ageing/afu022
20. Pereverzev A.P., Ostoumova O.D., Isayev R.I., Tkacheva O.N., Kotovskaya Yu.V. Drug-induced delirium in elderly and senile patients. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2019;119(7):120–127. (in Russ.) https://doi.org/10.17116/jnevro2019119071120
21. Zabolotskikh I.B., Gorobets E.S., Grigoriev E.V., Kozlov I.A., Kotovskaya Yu.V., Lebedinskiy K.M. et al. Perioperative management of elderly and senile patients. Anesthesiologiya i reanimatologiya. 2018;(1): 5–20. (in Russ.) https://doi.org/10.17116/anaesthesiology201801-0215
22. Jans I.S., Oudewortel L., Brandt P.M., van Gool W.A. Severe, Persistent and Fatal Delirium in Psychogeriatric Patients Admitted to a Psychiatric Hospital. Dement. Geriatr. Cogn. Disord. Extra. 2015;5:253–264. https://doi.org/10.1159/000381847
23. Young J., Murthy L., Westby M., Akunne A., O’Mahony R. Guideline Development Group. Diagnosis, prevention, and management of delirium: summary of NICE guidance. BMJ. 2010;341:c3704. https://doi.org/10.1136/bmj.c3704
24. Grover S., Avasthi A. Clinical Practice Guidelines for Management of Delirium in Elderly. Indian J. Psychiatry. 2018;60(Suppl 3):S329-S340. https://doi.org/10.4103/0019-5545.224473
25. Monastero R., Camarda C., Pipia C., Camarda R. Visual hallucinations and agitation in Alzheimer’s disease due to memantine: report of three cases. J. Neurol. Neurosurg. Psychiatry. 2007;78(5):546. https://doi.org/10.1136/jnnp.2006.096420
26. Roy K., Warnick S.J., Balon R. Catatonia Delirium: 3 Cases Treated With Memantine. Psychosomatics. 2016;57(6):645–650. https://doi.org/10.1016/j.psym.2016.08.001
Review
For citations:
Tkacheva O.N., Cherdak M.A., Mkhitaryan E.A. Management of the predementia stage of Alzheimer’s disease, complicated with hypoactive delirium. Russian neurological journal. 2020;25(6):40-46. (In Russ.) https://doi.org/10.30629/2658-7947-2020-25-6-40-46
Views:
857
Email this article 